The role of innate lymphoid cells in chronic respiratory diseases
AT Hsu, TA Gottschalk, E Tsantikos… - Frontiers in …, 2021 - frontiersin.org
The lung is a vital mucosal organ that is constantly exposed to the external environment, and
as such, its defenses are continuously under threat. The pulmonary immune system has …
as such, its defenses are continuously under threat. The pulmonary immune system has …
Evaluating triple ICS/LABA/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies
L Calzetta, BL Ritondo, P de Marco… - Expert Review of …, 2021 - Taylor & Francis
Objectives In some studies comparing triple with dual combination therapies in COPD there
might be a possible effect of inhaler bias resulting from different inhaler devices being used …
might be a possible effect of inhaler bias resulting from different inhaler devices being used …
[HTML][HTML] β2-adrenoreceptor agonist ameliorates mechanical allodynia in paclitaxel-induced neuropathic pain via induction of mitochondrial biogenesis
N Chen, MM Ge, DY Li, XM Wang, DQ Liu… - Biomedicine & …, 2021 - Elsevier
Chemotherapy-induced neuropathic pain is a debilitating and common side effect of cancer
treatment and so far no effective drug is available for treatment of the serious side effect …
treatment and so far no effective drug is available for treatment of the serious side effect …
LABA/LAMA as first-line therapy for COPD: a summary of the evidence and guideline recommendations
M Miravitlles, T Kawayama, M Dreher - Journal of Clinical Medicine, 2022 - mdpi.com
Inhaled bronchodilators (alone or in combination) are the cornerstone of treatment for
symptomatic patients with COPD, either as initial/first-line treatment or for second …
symptomatic patients with COPD, either as initial/first-line treatment or for second …
Exacerbations and real-world outcomes after single-inhaler triple therapy of Budesonide/Glycopyrrolate/Formoterol Fumarate, Among Patients with COPD: results from …
C Strange, J Tkacz, J Schinkel, B Lewing… - … Journal of Chronic …, 2023 - Taylor & Francis
Purpose Triple therapy to prevent exacerbations from chronic obstructive pulmonary disease
(COPD) is associated with improved health compared to single and dual-agent therapy in …
(COPD) is associated with improved health compared to single and dual-agent therapy in …
Progression of the PI3K/Akt signaling pathway in chronic obstructive pulmonary disease
Y Liu, H Kong, H Cai, G Chen, H Chen… - Frontiers in …, 2023 - frontiersin.org
Chronic Obstructive Pulmonary Disease (COPD) is a chronic respiratory disease
characterized by a slow progression and caused by the inhalation of harmful particulate …
characterized by a slow progression and caused by the inhalation of harmful particulate …
Review of drug development guidance to treat chronic obstructive pulmonary disease: US and EU perspectives
A van Haarst, L McGarvey… - Clinical Pharmacology & …, 2019 - Wiley Online Library
Chronic obstructive pulmonary disease (COPD) remains a leading cause of death
worldwide, yet only one new drug class has been approved in the last decade. However …
worldwide, yet only one new drug class has been approved in the last decade. However …
Impact of COPD exacerbations and burden of disease in Spain: AVOIDEX Study
JJ Soler-Cataluña, JL Izquierdo… - … Journal of Chronic …, 2023 - Taylor & Francis
Purpose Chronic obstructive pulmonary disease (COPD) is characterized by high morbidity
and mortality, with a considerable consumption of healthcare resources (HRU). This study …
and mortality, with a considerable consumption of healthcare resources (HRU). This study …
Benefit/risk profile of single-inhaler triple therapy in COPD
J Bourbeau, M Bafadhel, NC Barnes… - … Journal of Chronic …, 2021 - Taylor & Francis
Chronic obstructive pulmonary disease (COPD) is associated with major healthcare and
socioeconomic burdens. International consortia recommend a personalized approach to …
socioeconomic burdens. International consortia recommend a personalized approach to …
Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized …
GT Ferguson, N Brown, C Compton, TC Corbridge… - Respiratory …, 2020 - Springer
Background The comparative efficacy of inhaled corticosteroid/long-acting muscarinic
antagonist/long-acting β 2-agonist (ICS/LAMA/LABA) triple therapy administered via single …
antagonist/long-acting β 2-agonist (ICS/LAMA/LABA) triple therapy administered via single …